This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (66)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Conflict of Interest  • Medical Education  • Medical Ethics  • Alert me on articles by topic

Arnold S. Relman, MD

JAMA. 2001;285:2009-2012.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The pharmaceutical industry has gone too far. It is assuming a role in continuing medical education (CME) that is inappropriate for an industry with a vested interest in selling prescription drugs. Worse, many medical educational institutions not only allow the industry's encroachments but also welcome and even solicit pharmaceutical company participation in programs that should be the profession's sole responsibility. As a result, CME is now so closely linked with the marketing of pharmaceuticals that its integrity and credibility are being questioned. The problem is not new, but it has recently grown to alarming proportions.

Representatives of the pharmaceutical companies say their intention is simply to generate goodwill by helping the providers of CME with the costs of educational programs. That claim might be believable were financial assistance the total extent of their help and were the curriculum content and the educational event totally unaffected by . . . [Full Text of this Article]

Author Affiliation: Department of Medicine, Channing Laboratory, Harvard Medical School and Brigham and Women's Hospital, Boston, Mass.

RELATED LETTERS

The Pharmaceutical Industry and Continuing Education
George Dermksian, Augusto Sarmiento, Ton J. Cleophas, Ruudje C. Cleophas, Diane J. Madlon-Kay, and Arnold S. Relman
JAMA. 2001;286(3):302-304.
EXTRACT | FULL TEXT  

Reforming Graduate Medical Education
Betrand M. Bell
JAMA. 2002;287(6):715.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Industry Strongly Supports Continuing Medical Education
Alan F. Holmer
JAMA. 2001;285(15):2012-2014.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Medical Professionalism in a Commercialized Health Care Market
Relman
JAMA 2007;298:2668-2670.
FULL TEXT  

Experience of VA Psychiatrists With Pharmaceutical Detailing of Antipsychotic Medications
Sernyak and Rosenheck
Psychiatr. Serv. 2007;58:1292-1296.
ABSTRACT | FULL TEXT  

Is continuing medical education a drug-promotion tool?: YES
Steinman and Baron
cfp 2007;53:1650-1653.
FULL TEXT  

La formation medicale continue est-elle un outil de promotion pharmaceutique?: OUI
Steinman and Baron
cfp 2007;53:1654-1657.
FULL TEXT  

Conflict of Interest in Clinical Practice
Tonelli
Chest 2007;132:664-670.
ABSTRACT | FULL TEXT  

Optimizing Outcomes in Psychopharmacology Continuing Medical Education (CME): Measuring Learning and Attitudes That May Predict Knowledge Translation into Clinical Practice
Stahl et al.
Focus 2006;4:487.
ABSTRACT | FULL TEXT  

Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
Steinman et al.
ANN INTERN MED 2006;145:284-293.
ABSTRACT | FULL TEXT  

The 'Pinking' of Viagra Culture: Drug Industry Efforts to Create and Repackage Sex Drugs for Women
Hartley
Sexualities 2006;9:363-378.
ABSTRACT  

Medical Students' Exposure to and Attitudes About Drug Company Interactions: A National Survey
Sierles et al.
JAMA 2005;294:1034-1042.
ABSTRACT | FULL TEXT  

The Role of the Pharmaceutical Industry in Teaching Psychopharmacology: A Growing Problem
Brodkey
Acad. Psychiatry 2005;29:222-229.
ABSTRACT | FULL TEXT  

Excess in the pharmaceutical industry
Angell
CMAJ 2004;171:1451-1453.
FULL TEXT  

Doctors and Drug Companies
Blumenthal
NEJM 2004;351:1885-1890.
FULL TEXT  

Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative
Majumdar et al.
JAMA 2004;292:1983-1988.
ABSTRACT | FULL TEXT  

State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction
Patel et al.
J Am Coll Cardiol 2004;44:192-198.
ABSTRACT | FULL TEXT  

Industry Funding for Continuing Medical Education: Is It Ethical?
Heaphy and Marrow
Arch Ophthalmol 2004;122:771-773.
FULL TEXT  

Ethical Concerns in Industry Support of Continuing Medical Education: The Con Side
Packer and Parke
Arch Ophthalmol 2004;122:773-776.
FULL TEXT  

Manufacturing Desire:: The Commodification of Female Sexual Dysfunction
Fishman
Social Studies of Science 2004;34:187-218.
ABSTRACT  

Defending Professional Independence: ACCME's Proposed New Guidelines for Commercial Support of CME
Relman
JAMA 2003;289:2418-2420.
FULL TEXT  

Clinical trial end points: On the road to nowhere?
Holloway and Dick
Neurology 2002;58:679-686.
ABSTRACT | FULL TEXT  

Physician-Industry Relations. Part 1: Individual Physicians
Coyle and for the Ethics and Human Rights Committee, America
ANN INTERN MED 2002;136:396-402.
ABSTRACT | FULL TEXT  

Physician-Industry Relations. Part 2: Organizational Issues
Coyle and for the Ethics and Human Rights Committee, America
ANN INTERN MED 2002;136:403-406.
ABSTRACT | FULL TEXT  

From Clinical Trial to Prescription
Carpenter
Arch Gen Psychiatry 2002;59:282-285.
ABSTRACT | FULL TEXT  

Reforming Graduate Medical Education
Bell
JAMA 2002;287:715-715.
FULL TEXT  

Sponsorship, Authorship, and Accountability
Landow et al.
NEJM 2002;346:290-292.
FULL TEXT  

Reimbursement as Incentive to Improve Physicians' Quality of Care
Finestone et al.
JAMA 2001;286:1575-1575.
FULL TEXT  

ACCME standards for commercial support--time for a change?
Parmley
J Am Coll Cardiol 2001;38:916-917.
FULL TEXT  

The Pharmaceutical Industry and Continuing Education
Dermksian et al.
JAMA 2001;286:302-304.
FULL TEXT